The effectiveness of Vitagnos, Gabapentin and Paroxetine on early menopause complications

Comparison of the effectiveness of Vitagnos, Gabapentin and Paroxetine on the early complications of menopause in women: a double-blind clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181208041882N16

Enrollment

Registered

2023-10-28

Start date

2018-01-21

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early complications of menopause. Menopausal and other perimenopausal disorders

Interventions

Intervention 1: Intervention group: Patients suffering from early complications of menopause use gabapentin 100 mg orally daily for 8 weeks. Intervention 2: Intervention group: Patients suffering from

Eligibility

Sex/Gender

Female

Age

45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 45 to 60 years Amenorrhea for at least 12 months At least 3 hot flushes in 24 hours

Exclusion criteria

Exclusion criteria: Women with abnormal menopause Patients with chronic diseases (thyroid disease, psychosomatic disease, pheochromocytoma, carcinoid, leukemia, cancer and other known systemic diseases such as hypertension, diabetes, heart diseases) Consumption of hormones and supplements (containing estrogen-like compounds such as soy)

Design outcomes

Primary

Measure	Time frame
Menopause symptoms. Timepoint: Week 0, 4 and 8. Method of measurement: based on Kupperman Index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Heydari

Yazd University of Medical Sciences

b.heydari@ssu.ac.ir+98 35 3820 3410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026